Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study.
Nobuya InagakiTakaaki NishimotoYoichi NishiyaDaisuke NittaPublished in: Expert opinion on drug safety (2022)
The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT03761797) [Figure: see text] [Figure: see text].